JACKSONVILLE, Fla. — The Florida Society of Ophthalmology (FSO),the preeminent professional association for medical and osteopathic physicians who specialize in vision care, is pleased to announce that David A. Eichenbaum, MD received the Michael R. Redmond, MD Outstanding Young Ophthalmologist Award at its Annual Meeting, Masters in Ophthalmology 2015, June 26-28 in Palm Beach, Fla.
Read more...

This is a one hour show about research on treatments for blindness. It features an excellent panel of experts: Eric Kandel of Columbia University, Sanford Greenberg, Chairman of the Board of Governors of Johns Hopkins Wilmer Eye Institute ; Jean Bennett; Steven Schwartz of the Jules Stein Eye Institute; Eberhart Zrenner & Carla Shatz of Stanford University.
Read more...

Diabetic retinopathy has been a major cause of vision loss in working-age adults. To date, there have been effective treatments to reduce progression of diabetic retinopathy, but there has so far been no way to reverse the disease process. In the recent pivotal RISE and RIDE trials, monthly Lucentis was shown to actually improve the stage of diabetic retinopathy over 3 years. It is the first FDA-approved treatment to publish this finding.
Read more...

Diabetic macular edema is a leading cause of vision loss among working-age adults in the U.S., and we are pleased to be able to offer a new treatment option to these patients. Treatment with EYLEA can help improve and maintain vision with every 8 week dosing after 5 initial monthly doses. EYLEA is the first VEGF inhibitor approved for dosing on a less than monthly basis for the treatment of DME.
Read more...